Ardelyx, Inc. (ARDX)

8.72 +1.93 (+28.42%) At close: 04:00PM EDT

Ardelyx, Inc.

400 Fifth Avenue
Suite 210
Waltham, MA 02451
United States
510 745 1700
https://www.ardelyx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 267

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael G. Raab	President, CEO & Director	1.03M	N/A	1965
Ms. Elizabeth A. Grammer Esq.	Chief Legal & Administrative Officer and Secretary	668.25k	N/A	1964
Dr. Laura A. Williams M.D., M.P.H.	Chief Medical Officer	664.81k	N/A	1964
Mr. Justin A. Renz CPA, MBA	Chief Financial & Operations Officer	623.7k	N/A	1972
Mr. Robert Felsch	Senior VP of Finance & Chief Accounting Officer	N/A	N/A	N/A
Ms. Caitlin Lowie	Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Mike Kelliher	Executive Vice President of Corporate Development & Strategy	N/A	N/A	1977
Ms. Charon Spencer Sr.	Chief Human Resources Officer	N/A	N/A	N/A
Mr. David P. Rosenbaum	Chief Development Officer	645.4k	N/A	1961
Mr. Robert C. Blanks	Chief Regulatory Affairs & Quality Assurance Officer	590.8k	N/A	1960

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Corporate governance

Ardelyx, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.